22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › DIANTHUS THERAPEUTICS INC. › 2024-2025

DIANTHUS THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and DIANTHUS THERAPEUTICS INC.’s Form 8-K, filed May 22, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 138Asset managers, any item
  • 621Fund votes
  • May 22, 2025Meeting date

Results at a glance

Meeting of May 22, 2025: 4 items on DIANTHUS THERAPEUTICS INC.’s Form 8-K, filed May 22, 2025: 2 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (12.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore DIANTHUS THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by DIANTHUS THERAPEUTICS INC.

These tallies are DIANTHUS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

DIANTHUS THERAPEUTICS INC. — official shareholder meeting results, meeting held May 22, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Marino Garcia 23,703,737---- 2,122,2201,996,674 92%Passed (calculated)—
Elect Director: Paula Soteropoulos 22,695,868---- 3,130,0891,996,674 88%Passed (calculated)—
2. Advisory Vote on Executive Compensation 22,132,0313,684,7979,129 --1,996,674 86%Approved—
3. Ratification of Appointment of Independent Registered Public Accounting Firm 27,812,7361,7068,189 ---- 99.9%Approved—

Source: DIANTHUS THERAPEUTICS INC., Form 8-K, filed with the SEC on May 22, 2025 — read the filing on EDGAR.

How asset managers voted at the DIANTHUS THERAPEUTICS INC. 2024-2025 meeting

138 asset managers disclosed a vote on at least one DIANTHUS THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Marino Garcia

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 23,703,737WITHHELD: 2,122,220
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Marino Garcia

DIANTHUS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Marino Garcia”): 23,703,737 for, 2,122,220 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,500,416 for, 61,710 withheld.

FOR
FOR: 4,500,416WITHHOLD: 61,710
Largest asset managers voting on “To elect Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders a” at DIANTHUS THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity2,982,1580 00For
AllianceBernstein557,5850 00For
Vanguard446,1190 00For
Charles Schwab164,0970 00For
Principal110,3640 00For
BlackRock60,0350 00For
Northern Trust50,5730 00For
Equitable34,7180 00For
American Century00 020,363Withhold
State Street17,4920 020For
Lincoln Financial17,4000 00For
TIAA13,4650 00For
Pacific Life11,7370 00For
Bridge Builder Trust10,3190 00For
AuguStar00 08,062Withhold
Goldman Sachs7,4320 00For
Global X6,5230 00For
John Hancock00 06,432Withhold
AIG/SunAmerica00 05,324Withhold
ProShares00 04,757Withhold
ALPS ETF Trust00 04,375Withhold
SEI3,9000 00For
DWS00 03,559Withhold
QUANTITATIVE MASTER SERIES LLC2,6860 00For
Calvert00 02,342Withhold

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Paula Soteropoulos

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 22,695,868WITHHELD: 3,130,089
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Paula Soteropoulos

DIANTHUS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Paula Soteropoulos”): 22,695,868 for, 3,130,089 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 3,757,084 for, 805,042 withheld.

FORWITHHOLD
FOR: 3,757,084WITHHOLD: 805,042
Largest asset managers voting on “To elect Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders a” at DIANTHUS THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity2,982,1580 00For
AllianceBernstein00 0557,585Withhold
Vanguard446,1190 00For
Charles Schwab164,0970 00For
Principal00 0110,364Withhold
BlackRock60,0350 00For
Northern Trust00 050,573Withhold
Equitable9,9080 024,810Mixed
American Century00 020,363Withhold
State Street17,4920 020For
Lincoln Financial17,4000 00For
TIAA13,4650 00For
Pacific Life11,7370 00For
Bridge Builder Trust10,3190 00For
AuguStar00 08,062Withhold
Goldman Sachs7,4320 00For
Global X6,5230 00For
John Hancock00 06,432Withhold
AIG/SunAmerica00 05,324Withhold
ProShares00 04,757Withhold
ALPS ETF Trust00 04,375Withhold
SEI3,9000 00For
DWS00 03,559Withhold
QUANTITATIVE MASTER SERIES LLC2,6860 00For
Calvert00 02,342Withhold

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

86% Approved · of votes cast

FOR 86%AGAINST
FOR: 22,132,031AGAINST: 3,684,797

Prior year: 99.9% for (May 23, 2024 meeting) ▼ 14.1 pts

Details: description as filed, official tally, votes by 138 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation paid to our named executive officers; and

DIANTHUS THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 22,132,031 for, 3,684,797 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 42 asset managers voting on “To approve, on an advisory basis, the compensation paid to our named executive officers; and” at DIANTHUS THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity2,982,1580 00For
AllianceBernstein0557,585 00Against
Vanguard0446,119 00Against
Charles Schwab164,0970 00For
Principal0110,364 00Against
BlackRock60,0350 00For
Northern Trust50,5730 00For
Equitable9,90824,810 00Mixed
American Century020,363 00Against
State Street17,49220 00For
Lincoln Financial17,4000 00For
TIAA13,4650 00For
Pacific Life11,7370 00For
Bridge Builder Trust10,3190 00For
AuguStar00 8,0620Abstain
Goldman Sachs07,432 00Against
Global X6,5230 00For
John Hancock06,432 00Against
AIG/SunAmerica05,324 00Against
ProShares04,757 00Against
ALPS ETF Trust04,375 00Against
SEI3,9000 00For
DWS03,559 00Against
QUANTITATIVE MASTER SERIES LLC2,6860 00For
Calvert02,342 00Against

Fund voting reports, all 42 managers: 3,352,575 for, 1,201,489 against, 8,062 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 112 asset managers voting on “To approve, on an advisory basis, the compensation paid to our named executive officers; and” at DIANTHUS THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,053,3420 00For
RA CAPITAL MANAGEMENT, L.P.2,866,7330 00For
Fairmount Funds Management LLC2,700,6910 00For
Octagon Capital Advisors LP2,341,6670 00For
Deep Track Capital, LP2,341,6130 00For
VR Adviser, LLC1,744,3730 00For
Bain Capital Life Sciences Investors, LLC1,689,3740 00For
TCG Crossover Management, LLC1,501,6240 00For
5AM Venture Management, LLC1,027,7110 00For
AllianceBernstein0863,462 00Against
Vestal Point Capital, LP0769,639 00Against
Catalio Capital Management, LP535,5390 00For
Point720481,235 00Against
Citadel441,3640 00For
GEODE CAPITAL MANAGEMENT, LLC381,0540 00For
GREAT POINT PARTNERS LLC275,0000 00For
Janus Henderson0262,148 00Against
State Street254,5201,535 00For
Candriam S.C.A.0248,610 00Against
BlackRock240,0335,282 00For
Woodline Partners LP237,5550 00For
GV Management Company, L.L.C.208,6970 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.0189,000 00Against
Charles Schwab172,9050 00For
SILVERARC CAPITAL MANAGEMENT, LLC0134,003 00Against

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 27,812,736AGAINST: 1,706
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

DIANTHUS THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 27,812,736 for, 1,706 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,554,064 for, 8,062 abstained.

FOR
FOR: 4,554,064ABSTAIN: 8,062
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR T” at DIANTHUS THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity2,982,1580 00For
AllianceBernstein557,5850 00For
Vanguard446,1190 00For
Charles Schwab164,0970 00For
Principal110,3640 00For
BlackRock60,0350 00For
Northern Trust50,5730 00For
Equitable34,7180 00For
American Century20,3630 00For
State Street17,5120 00For
Lincoln Financial17,4000 00For
TIAA13,4650 00For
Pacific Life11,7370 00For
Bridge Builder Trust10,3190 00For
AuguStar00 8,0620Abstain
Goldman Sachs7,4320 00For
Global X6,5230 00For
John Hancock6,4320 00For
AIG/SunAmerica5,3240 00For
ProShares4,7570 00For
ALPS ETF Trust4,3750 00For
SEI3,9000 00For
DWS3,5590 00For
QUANTITATIVE MASTER SERIES LLC2,6860 00For
Calvert2,3420 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Largest DIANTHUS THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 32,125,933 shares outstanding at the time of that meeting.

Fund voting reports: top DIANTHUS THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation paid to our named executive officers; and”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 9.28%
2AllianceBernstein 1.74%
3Vanguard 1.39%
4Charles Schwab 0.51%
5Principal 0.34%
6BlackRock 0.19%
7Northern Trust 0.16%
8Equitable 0.11%
9American Century 0.06%
10State Street 0.05%
Institutional-manager reports: top DIANTHUS THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation paid to our named executive officers; and”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 12.62%
2RA CAPITAL MANAGEMENT, L.P. 8.92%
3Fairmount Funds Management LLC 8.41%
4Octagon Capital Advisors LP 7.29%
5Deep Track Capital, LP 7.29%
6VR Adviser, LLC 5.43%
7Bain Capital Life Sciences Investors, LLC 5.26%
8TCG Crossover Management, LLC 4.67%
95AM Venture Management, LLC 3.20%
10AllianceBernstein 2.69%

Reported DIANTHUS THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

DIANTHUS THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)4,482,609 13.95%Form 13F, quarter ended March 31, 2025
Sirenia Capital Management LP2,798,122 8.71%Schedule 13G, filed May 15, 2026
RA Capital Management, L.P.2,611,733 8.13%Schedule 13G, filed May 15, 2026
Wellington Management Group LLP2,595,783 8.08%Schedule 13G, filed May 15, 2026
Fairmount Funds Management LLC2,139,635 6.66%Schedule 13D, filed November 25, 2025
Avidity Partners Management LP2,104,184 6.55%Schedule 13D, filed November 19, 2025
BlackRock1,615,801 5.03%Form 13F, quarter ended March 31, 2025
TCG Crossover GP II, LLC1,501,624 4.67%Schedule 13G, filed May 15, 2025
Point721,486,944 4.63%Form 13F, quarter ended March 31, 2025
BCLS Fund III Investments, LP1,315,892 4.10%Schedule 13G, filed November 14, 2025

Percentages above are of 32,125,933 shares outstanding, as reported by DIANTHUS THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At DIANTHUS THERAPEUTICS INC.'s shareholder meeting held May 22, 2025, in the 2024-2025 proxy season, 138 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 621 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to our named executive officers; and — DIANTHUS THERAPEUTICS INC.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: DIANTHUS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DIANTHUS THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

DIANTHUS THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “DIANTHUS THERAPEUTICS (DNTH) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/dianthus-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.